StockData
Damora Therapeutics, Inc. logo

Damora Therapeutics, Inc. (DMRA) company profile

DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$22.56+0.06 (+0.29%)

Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%

About Damora Therapeutics

Pharmaceutical Preparations, SIC 2834

Damora Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on discovering and developing therapies for hematologic disorders. The company's pipeline centers on treatments for myeloproliferative neoplasms, which are chronic bone marrow disorders driven by myeloid cell proliferation. Its primary development programs include DMR-001, DMR-002, and DMR-003, which are monoclonal antibody candidates designed to selectively target mutant calreticulin. These investigational therapies aim to treat patients diagnosed with essential thrombocythemia and myelofibrosis.

The company operates in the United States and conducts its research and development programs through collaborative licensing arrangements. Its lead therapeutic candidates remain in preclinical development, with regulatory filings planned across multiple target indications. Damora Therapeutics maintains its principal executive offices in Waltham, Massachusetts.

Summary of the business section of Damora Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Damora Therapeutics, Inc.
Headquarters
Waltham, MA
Address
100 Fifth Avenue, Suite 700 02451
Phone
(781) 281-9020
Employees
7, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
EY Godkendt Revisionspartnerselskab, Copenhagen, Denmark

Stock & identifiers

Ticker
DMRA
Former tickers
GLTO until Mar 10, 2026
Exchange
Nasdaq
IPO date
Oct 30, 2020
Shares outstanding
62M, Aug 7, 2026
Public float
$4.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Aug 30, 2024
SEC CIK
1800315
CUSIP
36322Q206
ISIN
US36322Q2066
FIGI
BBG00XMLGWC5
Share class FIGI
BBG00XMLGWD4
EIN
37-1957007

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jennifer JarrettDirector, President and CEO512,500
Hans T. SchambyeChief Executive Officer, Director4,682
Garrett WinslowGeneral Counsel2,289
Brian BurkavageSVP, Finance–
Sherwin SattarzadehChief Operating Officer190,376
L. Becker HewesChief Medical Officer264,629
Lori FirmaniChief Financial Officer931
Matthew KronmillerEVP Strategy and CBO–
Andrew ChengDirector–
Healthcare Fund II L.P. FairmountDirector8,713,000
Cameron TurtleDirector–
Christopher W. CainDirector–
Peter Evan HarwinDirector–
Funds Management LLC FairmountDirector–
Julianne BrunoDirector137,032
Healthcare Co-Invest V. L.P. FairmountDirector–
Michael LandsittelDirector–
David ShapiroDirector–
Jayson Donald Alexander DallasDirector–
Amit MunshiDirector4,793
Anne PrenerDirector–
Carl GoldfischerDirector1,049,055
Amy B. WechslerDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.30M$2.13M$708.98K$128–
FY2024$1.43M$1.23M$759.67K$26–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Hans T. Schambye, M.D., Ph.D.
Former President and Chief Executive Officer
$547.52K$678.59K$73.68K–$1.30M-9%
Lori Firmani
Chief Financial Officer
$311.25K$202.50K$22.46K$27.00K$563.21K+0%
Garrett Winslow
General Counsel
$400.40K$400.40K$26.96K$27.00K$854.76K-5%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 30, 2020
Offer price
$15.00
Securities offered
5,666,667
Gross proceeds
$85.00M
Exchange
Nasdaq
First trading day
Oct 29, 2020
First-day close
$15.000.0%
Lock-up ends (est.)
Apr 27, 2021

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had seven full-time employees, including one who holds a Ph.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 20, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 10, 2026Name changeName changed from Galecto, Inc. to Damora Therapeutics, Inc.
Nov 10, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 7, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 2, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 30, 2020IPOInitial public offering priced (424B4 prospectus)
Oct 23, 2020ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?